

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.8941 - EQT / WIDEX / JV

SECTION 1.2

Description of the concentration

- (1) On 9 January 2019, EQT VI Limited, and EQT Fund Management S.à r.l. (together, ***EQT***) and T&W Medical A/S (***T&W Medical***) notified the intended creation of a full function joint venture within the meaning of Article 3(4) EUMR. The joint venture will be jointly controlled by EQT and T&W Medical and will combine the activities of Sivantos Pte. Ltd. (Singapore) (***Sivantos***) and Widex A/S (***Widex***) and their respective subsidiaries under a newly incorporated joint venture entity.
- (2) Both Sivantos and Widex are active as global manufacturers and suppliers of hearing aids and hearing accessories.
- (3) Sivantos, a portfolio company of EQT VI, is based in Singapore, with certain manufacturing operations and R&D functions based in Germany. Widex is a privately held business headquartered in Lyngø, Denmark, where it has both production facilities and R&D functions.